As of 2025-03-20, the EV/EBITDA ratio of Pliant Therapeutics Inc (PLRX) is -0.26. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PLRX's latest enterprise value is 58.23 mil USD. PLRX's TTM EBITDA according to its financial statements is -219.95 mil USD. Dividing these 2 quantities gives us the above PLRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-03-18 | -0.28 |
| 2025-03-17 | -0.29 |
| 2025-03-14 | -0.24 |
| 2025-03-13 | -0.24 |
| 2025-03-12 | -0.25 |
| 2025-03-11 | -0.25 |
| 2025-03-10 | -0.21 |
| 2025-03-07 | -0.26 |
| 2025-03-06 | -0.25 |
| 2025-03-05 | -0.24 |
| 2025-03-04 | -0.19 |
| 2025-03-03 | -0.20 |
| 2025-02-28 | -0.77 |
| 2025-02-27 | -0.72 |
| 2025-02-26 | -0.68 |
| 2025-02-25 | -0.70 |
| 2025-02-24 | -0.66 |
| 2025-02-21 | -0.67 |
| 2025-02-20 | -0.65 |
| 2025-02-19 | -0.65 |
| 2025-02-18 | -0.64 |
| 2025-02-14 | -0.66 |
| 2025-02-13 | -0.73 |
| 2025-02-12 | -0.57 |
| 2025-02-11 | -0.54 |
| 2025-02-10 | -0.67 |
| 2025-02-07 | -1.98 |
| 2025-02-06 | -3.14 |
| 2025-02-05 | -3.31 |
| 2025-02-04 | -2.98 |
| 2025-02-03 | -2.93 |
| 2025-01-31 | -2.81 |
| 2025-01-30 | -2.78 |
| 2025-01-29 | -2.80 |
| 2025-01-28 | -2.85 |
| 2025-01-27 | -2.88 |
| 2025-01-24 | -2.85 |
| 2025-01-23 | -2.92 |
| 2025-01-22 | -2.85 |
| 2025-01-21 | -2.90 |
| 2025-01-17 | -2.93 |
| 2025-01-16 | -3.04 |
| 2025-01-15 | -3.33 |
| 2025-01-14 | -2.94 |
| 2025-01-13 | -3.09 |
| 2025-01-10 | -3.16 |
| 2025-01-08 | -3.32 |
| 2025-01-07 | -3.51 |
| 2025-01-06 | -3.48 |
| 2025-01-03 | -3.58 |